Summary In this study the effects of nine dihydrophenazine derivatives, relative to clofazimine (B663), on the N-formyl-L-methionyl-L-Ieucyl-L-phenylalanine (FMLP) stimulated release of superoxide anion and on the spontaneous generation of arachidonic acid by human neutrophils were investigated. Previous findings that the pro-oxidative activity of the agents depended largely on the substituion in position 2 of the phenazine molecule and on chlorination in the paraposition of the phenyl and anilino rings were confirmed. Only riminophena zines, but not aposafranone derivatives or the imidazophenazine B621, could enhance superoxide release from activated neutrophils. The lack of chlorination of the phenyl and anilino rings could be compensated for by chlorine substitution in position 7 of the phenazine core.
Summary In this study the effects of nine dihydrophenazine derivatives, relative to clofazimine (B663), on the N-formyl-L-methionyl-L-Ieucyl-L-phenylalanine (FMLP) stimulated release of superoxide anion and on the spontaneous generation of arachidonic acid by human neutrophils were investigated. Previous findings that the pro-oxidative activity of the agents depended largely on the substituion in position 2 of the phenazine molecule and on chlorination in the paraposition of the phenyl and anilino rings were confirmed. Only riminophena zines, but not aposafranone derivatives or the imidazophenazine B621, could enhance superoxide release from activated neutrophils. The lack of chlorination of the phenyl and anilino rings could be compensated for by chlorine substitution in position 7 of the phenazine core.
The priming effect of the agents on FMLP stimulated superoxide generation was completely prevented by the phospholipase A2 inhibitor 4-p-bromophenacyl bromide. Furthermore pro-oxidative activities correlated closely with a stimula tory effect of the agents on arachidonic acid release. It was therefore concluded that dihydrophenazine derivatives with pro-oxidative properties can prime neutrophils for FMLP-stimulated superoxide release by modulation of phospho lipase A 2 activity.
The dihydrophenazine compound clofazimine (B663; 3-(p-chloroanilino )-1 O-(p-chloro phenyl)-2, IO-dihydro-2-(isopropyliminophenazine)) is used for the treatment of leprosy due to its anti mycobacterial, as well as its immunosuppressive properties.' Apart from its direct antimicrobial activity it can also enhance host defence by increasing various phagocyte functions including the respiratory burst.2,3 It has also been fo und to augment the release of reactive oxidants4 as well as of prostaglandin E 2 from polymorphonuclear and mononuclear leucocytes,5,6 both potential mediators of immunosuppression. 7,8 The priming effect of c10fazimine on superoxide release by human neutrophils is stimulus nonspecific and has been observed with phorbol myristate acetate (PMA), N-formyl peptides, calcium ionophore, opsonized zymosan and arachidonic acid (AA).9 Clofazi mine can mobilize AA from membrane phospholipids of human neutrophils.10 AA in micromolar concentrations and by a mechanism which remains to be clearly elucidated, activates NADPH-oxidase, whereas at suboptimal concentrations it can prime neutro phils to subsequent stimulation with N-formyl peptides or the tumour promotor phorbol myristate acetate.11-14 Since phospholipase A 2 (PLA 2 ) can cleave AA from membrane phospholipids1 5 the priming effect of c10fazimine on the release of superoxide from neutrophils could be explained by modulation of the activity of this enzyme. 1 0
We have recently shown how structural modifications of the c10fazimine molecule can influence the release of reactive oxidants4 as well as the release of PGE 2 from neutrophils. 16, 17 The nature of the chemical group in position 2 of the phenazine ring was fo und to be particularly important for these activities. In the present study we have extended our previous investigations and attempted to correlate molecular structures with both pro-oxidative activity and the mobilization of AA by human neutrophils.
Methods

CHEMICALS AND REAGENTS
Unless otherwise indicated, these were obtained from Sigma Chemical Co., St Louis, Mo, USA.
SELECTION A NO SOL UBILIZA TION OF AGENTS
All dihydrophenazine derivatives investigated in this study were synthesized by J F O'Sullivan. On the basis of previously published and unpublished data, nine phenazine derivatives were selected to correlate structural manipulations with effects on the release of super oxide anion and AA by human neutrophils in vitro.16�18 The chemical structures of these derivatives are shown in Figure 1 . B663, B980, B670, B1865, B746, B718 and B402 1 are riminophenazines while B3722 and B685 are aposafranones, in which the nitrogen in position 2 of the phenazine molecule has been replaced by oxygen. B3722 has a hydroxyl group in position 3, and B685 a p-chlorinated anilino ring. B621 is an imidazophenazine in which the phenyl and anilino rings in position 10 and 3 respectively are not chlorinated.
Ten milligrammes of each compound was solubilized in 5 ml dimethyl sulphoxide and fu rther diluted in distilled water to the concentrations required. All agents were compared to the appropriate solvent control.
CELL PREP ARA TION
Neutrophils were obtained from heparinized venous blood (5U preservative-free heparin per ml), as previously described. 3 The cells were suspended in indicator-free HEPES (N-2-hydroxy-ethylpiperazine-N'-2-ethanesulphonic acid, 4·2 mM)-buffered Hanks' balanced
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Aposafranones Imidazophenazines salt solution (HBSS; GIBCO Laboratories, Grand Island, NY, pH 7·4) and contained > 90% viable neutrophils.
SUPEROXIDE-PRODUCTION BY PMNL
The reaction mixture contained I x 106 neutrophils, 0· 1 J.lM of the synthetic chemotactic tripeptide N-formyl-L-methionyl-L-Ieucyl-L-phenylalanine (FMLP), 0· 1 mM horse heart fe rricytochrome c (cyt-c; type VI) and the agent under investigation at a final concentration of 1 J.lgjml, or the corresponding solvent control in a final volume of 1 ml HBSS with or without 100 U of superoxide dismutase (SOD). After preincubation of the neutrophils at 37°C for 5 min, cyt-c and, where applicable, SOD was added fo llowed immediately by the test agents. FMLP was added after 5 min incubation at 37°C and the reaction was stopped after another 5 min by addition of 4 ml ice-cold phosphate-buffered saline (0· 15 M, pH 7· 1) followed by centrifugation of the tubes. The supernatants were assayed for reduced cyt-c in an SP 1700 UV spectrophotometer (Unicam, Cambridge, England) at 550 nm. The amount of reduced cyt-c was calculated by using an absorbance coefficient of 2·11 x 104 cm2jmmol.19 Superoxide-dependent reduction of cyt-c is expressed as the difference in cyt-c reduction between reaction mixtures with and without SOD, as nmoles of reduced cyt-c per 106 neutrophils.
To investigate the role of PLA 2 in the pro-oxidative effects of the dihydrophenazines, 4-p-bromophenacyl bromide (BPB), an inhibitor of PLA/o was added to the reaction mixture directly after SOD and ranged from 0·25 to 5·0 J.lM. Following an incubation of 30 min at 37°C, the test agents (1-5 J.lgjml) and stimulants were added as previously described.
CELL VIABILITY
Neutrophil viability was measured after a 30 min incubation with BPB, according to the release of lactic acid dehydrogenase (LDH), by a standard spectrophotometric pro cedure. 2 1
ARACHIDONIC ACID RELEASE BY NEUTROPHILS
This assay was performed as previously described with some minor modifications.1o Briefly, 2 x 107/ml neutrophils were incubated with 5 j.lCi/ml radiolabelled AA (5, 6, 8, 9, II, 12, 14, 15-3H(N), 100 Ci/mmol, New England Nuclear Corp., Boston, Mass.) for 30 min at 37°C, washed twice and resuspended in HBSS. After prewarming the cells for 30 min at 37°C the agents, administered at 10 j.lg/ml final concentration, or the correspond ing solvent control were added fo llowed by an incubation time of 10 min at 37°C. The final volume in each tube was 1 ml (HBSS). The reactions were terminated by the addition of 5 ml n-hexane/isopropanol/concentrated HCI (final concentration 0· 1 M) 300 : 200 : 4 (vol/vol/vol), fo llowed by vortexing. After incubation at 4°C overnight the tubes were again vortexed and centrifuged at 2200 x g for 5 min to separate the lipophilic and aqueous phases. The upper organic phase was collected and dried under a stream of nitrogen. The lipids were then redissolved in 100 j.ll of hexane/isopropanol 3: 2 (vol/vol). Aliquots of 10 j.ll were spotted onto silica gel 60 F 254 precoated thin layer chromatography (TLC) plates (Merck, Darmstadt, Federal Republic of Germany) together with 2·7 j.lg unlabelled AA standard to facilitate visual detection. The plates were developed in chloroform/acetone 96 : 4 (vol/vol) fo llowed by exposure to iodine vapours. The AA spots were localized and the silica removed and assayed for radioactivity. The results are expressed as fm oles 3H-AA/2 x 107 neutrophils.
EXPRESSION AND ANALYSES OF RESULTS
Results are expressed as mean values with standard error (SEM) for each series of experiments. Statistical analyses were performed by the Student's t-test (paired t statistics).
Results
SUPEROXIDE PRODUCTION BY PMNL
There was no spontaneous generation of superoxide from resting cells incubated with I j.lg/ml of the dihydrophenazine derivatives (results not shown). The effect of the test agents on superoxide generation of FMLP-activated neutrophils in comparison to clofazimine is shown in Figure 2 . Statistically significant stimulation was fo und with the riminophenazines only, i.e. clofazimine, B980, B1865, B746, B718, B402 1, with the exception ofB670. Neither of the aposafranones, B685 and B3722, nor the imidazophena zine B621, had any effect on the amount of superoxide released by neutrophils.
The PLA 2 inhibitor BPB, inhibited the generation of super oxide from neutrophils in a dose dependent fa shion (Figure 3) . In assays where BPB-treated cells were stimulated with 0· 1 j.lM FMLP, (Figure 3(b) ) the release of superoxide was only significantly inhibited at a concentration of 5 liM. However, if the cells were treated with c10fazimine (l lig/ml) prior to stimulation, superoxide generation was inhibited by BPB concentra tions greater than 0·5 liM, (Figure 3(d) ). Furthermore, BPB only affected superoxide generation from c1ofazimine-free unstimulated control cells between I and 5 liM BPB (Figure 3(a) ), whilst c10fazimine treated neutrophils exhibited a clear dose response inhibition of superoxide, which was significant at BPB concentrations as low as 0·25 liM (Figure 3(c) ). This BPB-mediated inhibitory effect on superoxide release by neutrophils could not be overcome by increasing the concentration of the dihydrophenazine derivatives to 5 lig/ml (results not shown).
CELL VIABILITY
A 30 min pre-incubation of BPB with neutrophils had no effect on the cell viability as measured by percentage release of LDH. BPB-free control cells released 4·3% (±0·3) LDH while cells subjected to BPB for 30 min yielded 5·0% (± 1'0) LDH.
ARACHIDONIC ACID RELEASE BY PMNL
The effects of the nine phenazine derivatives relative to c10fazimine on the release of arachidonic acid by unstimulated neutrophils are shown in Figure 4 . Statistically significant stimulation was observed only with the riminophenazines c1ofazimine, B1865, B746 and B402 1. Dose response studies of these agents over a concentration range of 0-1 0 Jig/ml showed significant dose related increases of AA release at drug concentrations equal to or greater than 5 Jig/ml (p < 0'05-p < 0·0 I).
Discussion
In the present study the effects of various dihydrophenazine derivatives on FMLP stimulated superoxide generation and spontaneous AA release of human neutrophils in comparison to clofazimine were investigated. Possible scavenging or catalytic effects of the test agents on the reduction of cyt-c were excluded using the O"2-generating xanthine xanthine oxidase system. B663 (clofazimine), B980, B670, B3722, B685 and B62 1 have previously been investigated for effects on superoxide release by neutrophils and results similar to those of the present study, have been observed.4, 16 Previous findings on the significance of the substitution in position 2 of the phenazine molecule were also confirmed, i.e. only riminophenazines were potentially pro-oxidative while the aposafra none derivatives B3722 and B685 and the imidazophenazine B62 1 were inactive. 4, 16, 17 However, this study indicated that the unchlorinated riminophenazines B670 and B718 had no effect on AA release by neutrophils compared to their chlorinated analogues B663 (clofazimine) and B746, which is also in accordance with previous findings. 16 Lack of chlorination of the anilino and phenyl rings in the paraposition could however be compensated for by a chlorine substituent in position 7 of the phenazine molecule as in BI865 and B402 1.
Although the specificity of BPB has been questioned,22 it is primarily a PLA 2 inhibitor and completely prevented the pro-oxidative effects of the test agents indicating the possible involvement ofPLA 2 in the priming mechanism . Furthermore those compounds that stimulated superoxide generation of FMLP-activated neutrophils also increased AA release from the cells, with the exception of the unchlorinated riminophenazines B670 and B718, which had no effect on AA mobilization. This discrepancy especially with B718 which significantly enhances superoxide generation, could be attributed to the absence and presence respectively of a stimulus (FMLP) in the AA and superoxide assays. It is probable that the riminophenazines investigated in this study mediate their pro-oxidative effects by modulation of PLA 2 activity which cleaves AA from membrane phospholipids as was previously fo und for clofazimine.10 However alternative pro-oxidative mecha nisms related to the redox properties of clofazimine and its analogues may also play a role. 2, 23 Some of the agents have previously been investigated for chemotherapeutic activity in mice experimentally infected with My cobacterium tuberculosis.24,25 The increase in median survival time of the treated mice relative to untreated controls was measured. Interestingly, the most effective agents were those which we have fo und to interact pro oxidatively with human phagocytes. Some discrepancies are evident, e.g. clofazimine (B663) at a daily dosage of 5 mg/kg body mass increased the median survival time by 210 days, while B746 at the same dosage did so by only 45 days.2 1 These observations could be attributed to differences in pharmacokinetic properties.
It is concluded that only chlorinated riminophenazines are potent stimulators of spontaneous AA release from neutrophil membrane phospholipids, possibly via modulation of PLA 2 activity. AA can mediate the priming effect of the agents on superoxide release from activated neutrophils.
